Mark Frattini's guest appearances

Mark Frattini

17th European Haematology Association (EHA) Congress

John Porter

Michael Keating

Jan Geissler

Willem Fibbe

Charles Mullighan

Jing Chen

Giora Sharf

OwlTail

ecancer talks to Dr Mark Frattini, at the 17th European Haematology Association Congress in Amsterdam, about a method of testing patients with acute myeloid leukaemia in order to identify drug sensitivity and resistance. The test looks at patient’s cells by placing them in a type of acid for four days, and then checking them with up to 60 agents to identify their response; agents used include novel agents and FDA approved agents. The results from this test build a personal treatment for each patient. The study was conducted in a retrospective fashion with 25 patients to show sensitivity and resistance to prior treatments. This did allow for new treatments to be identified for five patients in the study, generating enough response to allow for bone marrow transplants. Dr Frattini now hopes to put this test into a prospective setting with a phase 1 clinical trial.

ecancer talks to Dr Mark Frattini, at the 17th European Haematology Association Congress in Amsterdam, about a method of testing patients with acute myeloid leukaemia in order to identify drug sensitivity and resistance. The test looks at patient’s cells by placing them in a type of acid for four days, and then checking them with up to 60 agents to identify their response; agents used include novel agents and FDA approved agents. The results from this test build a personal treatment for each patient. The study was conducted in a retrospective fashion with 25 patients to show sensitivity and resistance to prior treatments. This did allow for new treatments to be identified for five patients in the study, generating enough response to allow for bone marrow transplants. Dr Frattini now hopes to put this test into a prospective setting with a phase 1 clinical trial.

Drug sensitivity and resistance in acute myeloid leukaemia: Dr Mark Frattini – Memorial Sloan-Kettering Cancer Center